Cash and Cash Equivalents, at Carrying Value of Galmed Pharmaceuticals Ltd. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
Galmed Pharmaceuticals Ltd. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Galmed Pharmaceuticals Ltd. Cash and Cash Equivalents, at Carrying Value for the quarter ending 30 Sep 2025 was $3,314,000.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

Galmed Pharmaceuticals Ltd. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,314,000 30 Sep 2025 6-K 26 Nov 2025 2025 Q3
Q2 2025 $4,964,000 +$3,127,000 +170% 30 Jun 2025 6-K 28 Aug 2025 2025 Q2
Q4 2024 $4,652,000 +$1,791,000 +63% 31 Dec 2024 6-K 26 Nov 2025 2025 Q3
Q2 2024 $1,837,000 +$828,000 +82% 30 Jun 2024 6-K 28 Aug 2024 2024 Q2
Q4 2023 $2,861,000 +$845,000 +42% 31 Dec 2023 20-F 02 Apr 2025 2024 FY
Q2 2023 $1,009,000 -$971,000 -49% 30 Jun 2023 6-K 09 Aug 2023 2023 Q2
Q4 2022 $2,016,000 -$868,000 -30% 31 Dec 2022 20-F 04 Apr 2024 2023 FY
Q2 2022 $1,980,000 -$5,943,000 -75% 30 Jun 2022 6-K 04 Aug 2022 2022 Q2
Q4 2021 $2,884,000 -$4,063,000 -58% 31 Dec 2021 20-F 29 Mar 2023 2022 FY
Q2 2021 $7,923,000 +$2,370,000 +43% 30 Jun 2021 6-K 05 Aug 2021 2021 Q2
Q4 2020 $6,947,000 -$8,984,000 -56% 31 Dec 2020 20-F 02 May 2022 2021 FY
Q2 2020 $5,553,000 -$20,225,000 -78% 30 Jun 2020 6-K 06 Aug 2020 2020 Q2
Q4 2019 $15,931,000 -$8,228,000 -34% 31 Dec 2019 20-F 18 Mar 2021 2020 FY
Q2 2019 $25,778,000 +$19,627,000 +319% 30 Jun 2019 6-K 05 Aug 2019 2019 Q2
Q4 2018 $24,159,000 +$11,138,000 +86% 31 Dec 2018 20-F 12 Mar 2020 2019 FY
Q2 2018 $6,151,000 +$4,404,000 +252% 30 Jun 2018 6-K 05 Aug 2019 2019 Q2
Q4 2017 $13,021,000 +$9,924,000 +320% 31 Dec 2017 6-K 05 Aug 2019 2019 Q2
Q2 2017 $1,747,000 -$1,199,000 -41% 30 Jun 2017 6-K 02 Aug 2018 2018 Q2
Q4 2016 $3,097,000 -$1,059,000 -25% 31 Dec 2016 20-F 13 Mar 2019 2018 FY
Q2 2016 $2,946,000 -$4,378,000 -60% 30 Jun 2016 6-K 31 Jul 2017 2017 Q2
Q4 2015 $4,156,000 -$19,580,000 -82% 31 Dec 2015 20-F 13 Mar 2019 2018 FY
Q2 2015 $7,324,000 30 Jun 2015 6-K 23 Jun 2017 2016 Q2
Q4 2014 $23,736,000 +$23,599,000 +17226% 31 Dec 2014 20-F 13 Mar 2018 2017 FY
Q4 2013 $137,000 -$581,000 -81% 31 Dec 2013 20-F 23 Mar 2017 2016 FY
Q4 2012 $718,000 +$572,000 +392% 31 Dec 2012 20-F 22 Mar 2016 2015 FY
Q4 2011 $146,000 31 Dec 2011 20-F 31 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.